Squarepoint
FDMT icon

Squarepoint’s 4D Molecular Therapeutics FDMT Stock Holding History

Squarepoint’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Sell
25,576
-36,937
-59% -$360K ﹤0.01% 3710
2026
Q1 		$582K Sell
62,513
-9,208
-13% -$80.1K ﹤0.01% 3214
2025
Q4 		$538K Buy
71,721
+24,884
+53% +$252K ﹤0.01% 3154
2025
Q3 		$407K Sell
46,837
-6,042
-11% -$36.1K ﹤0.01% 3418
2025
Q2 		$196K Buy
+52,879
New +$186K ﹤0.01% 3984
2024
Q4 		– Sell
-50,320
Closed -$544K – 5157
2024
Q3 		$544K Sell
50,320
-59,721
-54% -$991K ﹤0.01% 3028
2024
Q2 		$2.31M Buy
110,041
+95,422
+653% +$2.39M ﹤0.01% 1945
2024
Q1 		$466K Buy
+14,619
New +$373K ﹤0.01% 3097
2023
Q4 		– Sell
-47,749
Closed -$608K – 4143
2023
Q3 		$608K Buy
47,749
+33,056
+225% +$553K ﹤0.01% 2646
2023
Q2 		$266K Sell
14,693
-46,665
-76% -$859K ﹤0.01% 3039
2023
Q1 		$1.05M Sell
61,358
-768
-1% -$14.9K ﹤0.01% 1857
2022
Q4 		$1.38M Buy
+62,126
New +$960K 0.01% 1603

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Squarepoint's FDMT Position: Q2 2026 in Review

Squarepoint reduced its 4D Molecular Therapeutics (FDMT) stake by 59% in Q2 2026, selling an estimated $360K and leaving 25,576 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #3710.

Squarepoint first reported a position in FDMT in Q4 2022 and has held it in 12 quarters since. The position peaked at $2.31M in Q2 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Squarepoint held 25,576 shares of 4D Molecular Therapeutics worth $340K as of Q2 2026.
  • Squarepoint sold 36,937 4D Molecular Therapeutics shares in Q2 2026, an estimated $360K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3710 holding.
  • Squarepoint first reported a position in 4D Molecular Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • Squarepoint's 4D Molecular Therapeutics position peaked at $2.31M in Q2 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.